SoftBank Group (OTC:SFTBY) (OTC:SFTBF) is set to introduce a medical service in Japan that uses artificial intelligence to analyze personal medical data, including genetic information. The service will be launched through a joint venture with U.S. healthcare company Tempus AI Inc. (NASDAQ:TEM). Following the report, Tempus AI Inc.’s stock surged nearly 3% in pre-market hours trading.
What Happened: The joint venture, capitalized at 30 billion yen ($188 million), will be equally owned by SoftBank Group and Tempus AI. The venture is expected to commence operations as early as July and aims to start providing services within one to two years, reported Nikkei on Tuesday.
Tempus AI, through its analytical machine learning platform, enables physicians to make real-time, data-driven decisions to provide personalized ...